{"id":"W1990675339","doi":"10.1016/s0140-6736(14)60958-2","title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1761,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Ipilimumab; Internal medicine; Clinical endpoint; Adverse effect; Refractory (planetary science); Cohort; Clinical trial; Melanoma; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Surgery; Phases of clinical research; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}